Follow

Notice to attend Extraordinary General Meeting in Umecrine Cognition AB

07 July 2022 - 12:00

The shareholders in Umecrine Cognition AB, reg. no. 556698-3655, are hereby given notice to attend the extraordinary general meeting at 10:00 a.m. on Wednesday 10 August 2022. The meeting will be held through postal voting only.

Aktieägarna i Umecrine Cognition AB, org.nr 556698-3655, kallas härmed till extra bolagsstämma klockan 10.00 onsdagen den 10 augusti 2022. Stämman kommer att hållas enbart genom poströstning.

The complete Notice can be found on /Kallelsen i sin helhet finns på sidan:

www.umecrinecognition.com/en/investors/corporate-governance/extra-general-meeting-august-2022/

Provided by: MFN
Nasdaq First North GM Stockholm (Sweden)
Umecrine Cognition AB
Umecrine Cognition is developing pharmaceuticals against neurological disorders in the central nervous system, CNS that are caused by endogenous CNS-active steroids (neurosteroids)....
Learn more about company

Related news

We use cookies to make your experience using IPOhub better. By using our site you agree to our use of cookies. Learn More